Ovid Therapeutics OVID

Ovid Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations

$2.45+8.41%close on Oct. 28, 2026 · volume 2.1M · Yahoo Finance

Price, last 47 sessions

Aug. 24, 2026 to Oct. 28, 2026 · high $2.93 · low $2.15

Nothing published yet.

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

Market cap

$478.5 million

$2.45 x shares as of Aug. 11, 2026

Revenue, quarter

$0.7 million

ended June 30, 2026; year earlier $6.3 million

Revenue, fiscal year

$7.3 million

ended Dec. 31, 2025; prior $0.6 million

Net income, quarter

-$15.0 million

ended June 30, 2026; year earlier -$4.7 million

Net income, fiscal year

-$17.4 million

ended Dec. 31, 2025; prior -$26.4 million

Operating income, quarter

-$15.7 million

ended June 30, 2026; year earlier -$5.1 million

Operating income, fiscal year

-$42.4 million

ended Dec. 31, 2025; prior -$61.9 million

Diluted EPS, quarter

-$0.20

ended Sept. 30, 2024

Cash and equivalents

$11.3 million

as of June 30, 2026

From the company's SEC filings (XBRL). Market cap uses the latest cover-page share count.

Date	Firm	Rating	Target
Oct. 15, 2026	Wolfe Research	Outperform	$5.00
Oct. 9, 2026	Cantor Fitzgerald	Overweight
Oct. 6, 2026	Guggenheim	Buy	$7.00
Oct. 5, 2026	Guggenheim	Buy	$7.00
Sept. 11, 2026	HC Wainwright & Co.	Buy	$5.00
Aug. 3, 2026	Oppenheimer	Outperform	$9.00
April 15, 2026	Wedbush	Outperform	$7.00
April 9, 2026	HC Wainwright & Co.	Buy	$4.00
March 26, 2026	BTIG	Buy	$4.00
March 20, 2026	Wedbush	Outperform	$7.00
Dec. 22, 2025	LifeSci Capital	Outperform	$4.00
Dec. 22, 2025	HC Wainwright & Co.	Buy	$2.00
Dec. 11, 2025	Roth Capital	Buy	$3.00
Nov. 24, 2025	HC Wainwright & Co.	Buy	$2.00
Nov. 17, 2025	Leerink Partners	Outperform	$5.00

Source: Yahoo Finance. Dates are UTC.